News | December 02, 2023
Strides launches Icosapent Ethyl Acid Soft Gel capsules in partnership with Amneal
The product has been in-licensed from Strides and will be commercialized by Amneal
The product has been in-licensed from Strides and will be commercialized by Amneal
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
South Asia’s largest Trade Fair for pharma brought together over 50,000 visitors from across the globe, more than 1,500 exhibitors showcasing 10,000+ products and representation from over 80 countries
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
The newly established business will be looking for high-quality, mid- to late-stage assets, clinically focused on the United States market
Subscribe To Our Newsletter & Stay Updated
